Search
Phenindione Action Pathway
smpdb.ca/view/SMP0000655Drug actionPhenindione is a medication that is used as an anticoagulant. Anticoagulants are drugs that prevent the blood from coagulating and creating blood clots. … It is used to treat a variety of conditions, including cerebral and pulmonary embolisms, as well as cardiomyopathy.
Enzymes: Tissue factor, Coagulation factor VIIIFondaparinux.
smpdb.ca/view/SMP0000273Drug actionThese factors are joined by coagulation factor V and prothrombin. … This enzyme also catalyzes precursors of prothrombin and coagulation factors VII, IX and X to prothrombin and coagulation factors VII, IX and X.
Enzymes: Tissue factor, Coagulation factor VIIIHeparin.
smpdb.ca/view/SMP0000274Drug actionActivated antithrombin III will inactive prothrombin and factor Xa (also other proteases). … Heparin (also named unfractionated heparin or Clexane) is an anticoagulant medication.
Enzymes: Tissue factor, Coagulation factor VIIIEnoxaparin.
smpdb.ca/view/SMP0000272Drug actionThey also are not inactivated by platelet factor 4 and does not bind endothelial cells or macrophages thus are not degraded as fast. … The drug increases the inactivation of coagulation factors IXa, Xa and XIIa. This increases the antithrombin effects.
Enzymes: Tissue factor, Coagulation factor VIIIArdeparin Action Pathway
smpdb.ca/view/SMP0000275Drug actionArdeparin binds and increases antithrombin III activity and inactivates thrombin, factor Xa and coagulation factors XIIa, XIa, plasmin and kallikrein to prevent clot formation. … These properties increase ardeparin's bioavailability and give a more predictable anticoagulant activity.
Enzymes: Tissue factor, Coagulation factor VIIIBevacizumab VEGF Inhibitor Action Pathway
smpdb.ca/view/SMP0122788Drug actionIt targets vascular endothelial growth factor (VEGF) in the blood. When cancer grows and spreads, the blood and oxygen supplies become insufficient. … The cancer cells are starved of blood and oxygen, preventing the growth and spread of cancer.
Drugs: BevacizumabEnzymes: Vascular endothelial growth factor A, Vascular endothelial growth factor receptor 1Bevacizumab Action Pathway
smpdb.ca/view/SMP0000420Drug actionThe activated MAP kinase enters the nucleus and stimulates the expression of angiogenic factors resulting in increased cell proliferation, migration, permeability, invasion, and survival. … This in turns inhibits the MAP and IP3 and supresses angiogenesis.
Drugs: BevacizumabEnzymes: Vascular endothelial growth factor A, Vascular endothelial growth factor receptor 2Selenoamino Acid Metabolism
smpdb.ca/view/SMP0000029MetabolicThese 2 products combine to produce a cardiolipin and an ethanolamine. The L-1 phosphatidyl-glycerol can also interact with cardiolipin synthase resulting in a glycerol and a cardiolipin. … The major phospholipids of P. aeruginosa are phosphatidylethanolamine, phosphatidylglycerol, and cardiolipin.
Enzymes: Selenide, water dikinase 2Necroptosis
smpdb.ca/view/SMP0570184SignalingNecroptosis is initiated by the activation of death receptors such as TNF receptors (TNFRSF1A and TNFRSF10A) and FAS (TNFRSF6). … Moreover, interferons, such as interferon alpha, can also influence necroptotic signaling through the JAK1-STAT1 pathway, contributing to inflammation and immune responses.
Enzymes: Signal transducer and activator of transcription 1-alpha/beta, Tumor necrosis factorSorafenib Action Pathway
smpdb.ca/view/SMP0122742Drug actionIt is an inhibitor of the RAF kinase protein and cell surface kinases PDGF-beta receptor, VEGF 2 and 3 receptor (many sources also say VEGFR 1), c-KIT receptor, and FLT-3 receptor. … C-KIT and FLT-3 on tumor cells are inhibited causing their proliferation to stop and the PDGF and VEGF receptors on endothelial cells are inhibited to stop the growth of new blood vessels that bring blood
Enzymes: Vascular endothelial growth factor D, Platelet-derived growth factor D